Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Celldex Therapeutics (CLDX) EPS (Weighted Average and Diluted) (2019 - 2025)

Celldex Therapeutics (CLDX) has 10 years of EPS (Weighted Average and Diluted) data on record, last reported at -$1.23 in Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 73.24% year-over-year to -$1.23; the TTM value through Dec 2025 reached -$3.9, down 59.18%, while the annual FY2025 figure was -$3.9, 59.18% down from the prior year.
  • EPS (Weighted Average and Diluted) reached -$1.23 in Q4 2025 per CLDX's latest filing, down from -$1.01 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.34 in Q2 2021 and bottomed at -$1.23 in Q4 2025.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.67, with a median of -$0.63 recorded in 2023.
  • Peak YoY movement for EPS (Weighted Average and Diluted): skyrocketed 99.94% in 2021, then tumbled 126.47% in 2022.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.43 in 2021, then tumbled by 32.56% to -$0.57 in 2022, then tumbled by 47.37% to -$0.84 in 2023, then grew by 15.48% to -$0.71 in 2024, then plummeted by 73.24% to -$1.23 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$1.23 in Q4 2025, -$1.01 in Q3 2025, and -$0.85 in Q2 2025.